SIRT3 Attenuates MPTP-Induced Nigrostriatal Degeneration Via Enhancing Mitochondrial Antioxidant Capacity

Neurochemical Research

Volumn 40, Issue 3, 2015, Pages 600-608

  Liu, Lei ^a   Peritore, Carina ^a   Ginsberg, Jessica ^a   Kayhan, Merve ^a   Donmez, Gizem ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Behavior; GPx; Mitochondria; MPTP; Oxidative stress; Parkinson s disease; SIRT3; Sirtuins; SOD2

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIOXIDANT; GLUTATHIONE PEROXIDASE; MANGANESE SUPEROXIDE DISMUTASE; SIRTUIN 3; TYROSINE 3 MONOOXYGENASE; SCAVENGER; SIRT3 PROTEIN, MOUSE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY SIZE; BODY WEIGHT; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE EXACERBATION; DOPAMINERGIC NERVE CELL; FEMALE; FOOD INTAKE; FORCED SWIM TEST; GRIP STRENGTH; GRIP STRENGTH TEST; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MOTOR COORDINATION; MOTOR PERFORMANCE; MOUSE; MUSCLE STRENGTH; NERVE CELL DEGENERATION; NISSL STAINING; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; REPRODUCTIVE SUCCESS; ROTAROD TEST; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA PARS COMPACTA; TAIL SUSPENSION TEST; WESTERN BLOTTING; 129 MOUSE; ANIMAL; C57BL MOUSE; CORPUS STRIATUM; DEFICIENCY; KNOCKOUT MOUSE; METABOLISM; MITOCHONDRION; MPTP POISONING; PATHOLOGY; SUBSTANTIA NIGRA;

ANIMALS; ANTIOXIDANTS; CORPUS STRIATUM; FEMALE; FREE RADICAL SCAVENGERS; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOCHONDRIA; MPTP POISONING; SIRTUIN 3; SUBSTANTIA NIGRA;

EID: 84925487114     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-014-1507-8     Document Type: Article

References (33)

1. Moore DJ, West AB, Dawson VL, Dawson TM (2005) Molecular pathophysiology of Parkinson’s disease. Annu Rev Neurosci 28:57–87
2. Lees AJ, Hardy J, Revesz T (2009) Parkinson’s disease. Lancet 373(9680):2055–2066
3. Perier C, Vila M (2012) Mitochondrial biology and Parkinson’s disease. Cold Spring Harb Perspect Med 2(2):a009332
4. Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443(7113):787–795
5. Orrenius S, Gogvadze V, Zhivotovsky B (2007) Mitochondrial oxidative stress: implications for cell death. Annu Rev Pharmacol Toxicol 47:143–183
6. Donmez G, Guarente L (2010) Aging and disease: connections to sirtuins. Aging Cell 9(2):285–290
7. Haigis MC, Sinclair DA (2010) Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol 5:253–295
8. Bell EL, Guarente L (2011) The SirT3 divining rod points to oxidative stress. Mol Cell 42(5):561–568
9. Ahn BH, Kim HS, Song S, Lee IH, Liu J et al (2008) A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad Sci USA 105:14447–14452
10. Qiu X, Brown K, Hirschey MD, Verdin E, Chen D (2010) Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab 12:662–667
11. Someya S, Yu W, Hallows WC, Xu J, Vann JM et al (2010) Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell 143:802–812
12. Tao R, Coleman MC, Pennington JD, Ozden O, Park SH et al (2010) Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol Cell 40:893–904
13. Palacios OM, Carmona JJ, Michan S, Chen KY, Manabe Y et al (2009) Diet and exercise signals regulate SIRT3 and activate AMPK and PGC-1alpha in skeletal muscle. Aging 1(9):771–783
14. Hirschey MD, Shimazu T, Goetzman E, Jing E, Schwer B et al (2010) SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 464(7285):121–125
15. Jackson-Lewis V, Przedborski S (2007) Protocol for the MPTP mouse model of Parkinson’s disease. Nat Protoc 2(1):141–151
16. Chiba K, Peterson LA, Castagnoli KP, Trevor AJ, Castagnoli N Jr (1985) Studies on the molecular mechanism of bioactivation of the selective nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Drug Metab Dispos 13(3):342–347
17. Cleeter MW, Cooper JM, Schapira AH (1992) Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J Neurochem 58(2):786–789
18. Hantraye P, Brouillet E, Ferrante R, Palfi S, Dolan R et al (1996) Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat Med 2(9):1017–1021
19. Lombard DB, Alt FW, Cheng HL, Bunkenborg J, Streeper RS et al (2007) Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol Cell Biol 27(24):8807–8814
20. Cryan JF, Holmes A (2005) The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 4(9):775–790
21. Steru L, Chermat R, Thierry B, Simon P (1985) The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 85(3):367–370
22. Przedborski S, Jackson-Lewis V, Naini AB, Jakowec M, Petzinger G et al (2001) The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem 76(5):1265–1274
23. Nagatsu T, Levitt M, Udenfriend S (1964) Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis. J Biol Chem 239:2910–2917
24. Flynn JM, Melov S (2013) SOD2 in mitochondrial dysfunction and neurodegeneration. Free Radic Biol Med 62:4–12
25. Verdin E, Hirschey MD, Finley LW, Haigis MC (2010) Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. Trends Biochem Sci 35(12):669–675
26. Kim HS, Patel K, Muldoon-Jacobs K, Bisht KS, Aykin-Burns N et al (2010) SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 17(1):41–52
27. Piao Y, Kim HG, Oh MS, Pak YK (2012) Overexpression of TFAM, NRF-1 and myr-AKT protects the MPP(+)-induced mitochondrial dysfunctions in neuronal cells. Biochim Biophys Acta 1820(5):577–585
28. Zhang X, Zhou JY, Chin MH, Schepmoes AA, Petyuk VA et al (2010) Region-specific protein abundance changes in the brain of MPTP-induced Parkinson’s disease mouse model. J Proteome Res 9(3):1496–1509
29. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA et al (1999) Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46(4):598–605
30. Sedelis M, Hofele K, Auburger GW, Morgan S, Huston JP et al (2000) MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet 30(3):171–182
31. Balaban RS, Nemoto S, Finkel T (2005) Mitochondria, oxidants, and aging. Cell 120(4):483–495
32. Piantadosi CA, Suliman HB (2012) Redox regulation of mitochondrial biogenesis. Free Radic Biol Med 53(11):2043–2053
33. Ghosh N, Ghosh R, Mandal SC (2011) Antioxidant protection: a promising therapeutic intervention in neurodegenerative disease. Free Radic Res 45(8):888–905